Published in Prostate on July 01, 2007
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res (2010) 1.65
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett (2008) 1.13
Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer (2010) 1.11
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther (2014) 1.05
Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther (2011) 0.97
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer (2014) 0.95
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. J Immunother (2015) 0.87
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs (2015) 0.86
Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice. PLoS One (2012) 0.85
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
"Model t" cells: a time-tested vehicle for gene therapy. Front Immunol (2013) 0.82
A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (SlanDCs). PLoS One (2011) 0.82
T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc Natl Acad Sci U S A (2012) 0.81
Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells. J Oncol (2013) 0.81
Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) (2012) 0.80
A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One (2014) 0.79
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8. PLoS One (2014) 0.78
In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma. Endocrinology (2014) 0.78
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J Hematol Oncol (2017) 0.75
Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression. Oncotarget (2017) 0.75
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2012) 3.28
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology (2013) 1.77
Seebeck effect in magnetic tunnel junctions. Nat Mater (2011) 1.77
Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res (2005) 1.76
Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate (2006) 1.74
Advances in specific immunotherapy for prostate cancer. Eur Urol (2007) 1.70
Structural and functional insights into RAGE activation by multimeric S100B. EMBO J (2007) 1.59
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood (2007) 1.57
N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem (2002) 1.51
Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev (2010) 1.50
T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the HLA class II haplotype DRB1*0301/DQB1*0201. Arthritis Rheum (2007) 1.50
Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis (2004) 1.39
Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep (2005) 1.37
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 1.33
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A (2011) 1.31
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett (2005) 1.29
Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol (2011) 1.25
Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A (2009) 1.23
Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol (2012) 1.21
Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med (2006) 1.20
The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun (2011) 1.20
Characterization of prototype foamy virus gag late assembly domain motifs and their role in particle egress and infectivity. J Virol (2005) 1.18
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol (2003) 1.17
Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J (2007) 1.16
Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol (2005) 1.12
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget (2012) 1.11
S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun (2004) 1.11
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol (2006) 1.09
Modification of lupus-associated 60-kDa Ro protein with the lipid oxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading. Free Radic Biol Med (2005) 1.09
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res (2011) 1.07
The histone demethylase UTX regulates stem cell migration and hematopoiesis. Blood (2013) 1.06
Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol (2010) 1.05
Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem (2010) 1.05
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther (2013) 1.05
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica (2013) 1.05
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res (2007) 1.04
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother (2004) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology (2012) 1.03
Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol (2007) 1.02
Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate (2010) 1.02
Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell (2003) 1.02
Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol (2011) 1.02
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01
Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol (2003) 1.01
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer (2011) 1.01
Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun (2013) 1.01
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther (2011) 1.00
Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle-mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response. J Bone Miner Res (2012) 0.99
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol (2011) 0.99
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res (2010) 0.99
SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells. Mol Cancer (2011) 0.98
Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer (2002) 0.98
Transcriptional activation of the type I collagen genes COL1A1 and COL1A2 in fibroblasts by interleukin-4: analysis of the functional collagen promoter sequences. J Cell Physiol (2004) 0.98
T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol (2007) 0.98
Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther (2010) 0.98